Download PDF
Exp Clin Endocrinol Diabetes 2009; 117(8): 417-422
DOI: 10.1055/s-0029-1214386
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Impact of Disease Duration on Coronary Calcification in Patients with Acromegaly

B. L. Herrmann1 , 2 , M. Severing1 , A. Schmermund3 , C. Berg1 , Th. Budde4 , R. Erbel3 , K. Mann1
  • 1Department of Endocrinology and Division of Laboratory Research, University Duisburg-Essen, Germany
  • 2Division of Endocrinology and Diabetology, Technology Center, Bochum, Germany
  • 3Department of Cardiology, West-German Heart Center Essen, University Duisburg-Essen, Germany
  • 4Department of Internal Medicine/Cardiology, Alfried-Krupp-Hospital, Essen, Germany
Further Information

Publication History

received 08.12.2008 first decision 24.02.2009

accepted 24.02.2009

Publication Date:
16 April 2009 (online)

Also available at
    Permissions and Reprints

Abstract

It is well established, that the increased mortality in patients with acromegaly is due to cardiac diseases. Cardiomyopathy is the predominant cardiac alteration in patients with acromegaly. There are less data about coronary heart disease or coronary calcifications. Electron beam computed tomography (EBCT) is the standard imaging modality for identification of coronary artery calcifications (CAC) and can determine the extent and severity of coronary atherosclerosis. Coronary risk was evaluated by the Framingham risk score (FRS). The prospective study included 30 patients with acromegaly (mean age 53±14 year; 16 females, 14 males; BMI 28.1±3.6 kg/m2; mean±SD), 12 patients had active disease (IGF-1 751±338 μg/L; GH 25.6±36.4 μg/L), 9 were well-controlled (IGF-1 157±58 μg/L; GH 1.8±1.1 μg/L) under somatostatin analogue octreotide (n=5), dopamine agonists (n=2), and the GH receptor antagonist pegvisomant (n=2; GH levels were not determined in this subgroup) and 9 were cured IGF-1 (148±57 μg/L; GH 0.5±0.2 μg/L). Increased left ventricular muscle mass index (LVMI >132 g/m2) was focused in 53%, hypercholesterinemia in 63%, hypertension in 43%, diabetes mellitus/impaired glucose tolerance in 27%, and smokers in 53% (pack per year 9±15 yr). For quantification of CAC the EBCT was used and the Agatston calcium score was determined. Results were composed to established age and sex adjusted percentile distribution of CAC. CAC was present in 53%, high CAC score (75th percentile) in 37% and were categorized as cardiovascular high risk patients. FRS was related to the CAC score (p=0.008, r2=0.22) and the disease duration (p=0.002, r2=0.29). The CAC score correlated with LVMI (p=0.02, r2=0.17), the disease duration of acromegaly (p=0.004, r2=0.36), and the FRS (p=0.008, r2=0.22). Patients with a high CAC score had a longer disease duration of 9.6±4.7 versus 5.4±2.8 years with CAC<75th percentile (p=0.02). In summary, the disease duration and consequently the accompanying metabolic disorders appear to influence the degree of CAC in patients with acromegaly. The observations underline the importance of early and sufficient treatment of acromegaly in high risk patients.

Key words

acromegaly - coronary calcification - disease duration

References

  • 1 Melmed S. Acromegaly.  N Engl J Med. 1990;  322 966-977
    CrossrefPubMedGoogle Scholar
  • 2 Colao A, Baldelli R, Marzullo P. et al . Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.  J Clin Endocrinol Metab. 2000;  85 193-199
    CrossrefPubMedGoogle Scholar
  • 3 Clayton RN. Cardiovascular function in acromegaly.  Endocr Rev. 2003;  24 272-277
    CrossrefPubMedGoogle Scholar
  • 4 Colao A, Ferone D, Marzullo P. et al . Systemic complications of acromegaly: epidemiology, pathogenesis, and management.  Endocr Rev. 2004;  25 102-152
    CrossrefPubMedGoogle Scholar
  • 5 Herrmann BL, Bruch C, Saller B. et al . Occurrence of ventricular late potentials in patients with active acromegaly.  Clin Endocrinol (Oxf). 2001;  55 201-207
    CrossrefPubMedGoogle Scholar
  • 6 Lie JT. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients.  Am Heart J. 1980;  100 41-52
    CrossrefPubMedGoogle Scholar
  • 7 Otsuki M, Kasayama S, Yamamoto H. et al . Characterization of premature atherosclerosis of carotid arteries in acromegalic patients.  Clin Endocrinol (Oxf). 2001;  54 791-796
    CrossrefPubMedGoogle Scholar
  • 8 Erbel R, Schmermund A, Mohlenkamp S. et al . Electron-beam computed tomography for detection of early signs of coronary arteriosclerosis.  Eur Heart J. 2000;  21 720-732
    CrossrefPubMedGoogle Scholar
  • 9 Erbel R, Mohlenkamp S, Kerkhoff G. et al . Non-invasive screening for coronary artery disease: calcium scoring.  Heart. 2007;  93 1620-1629
    PubMedGoogle Scholar
  • 10 Schmermund A, Erbel R. Unstable coronary plaque and its relation to coronary calcium.  Circulation. 2001;  104 1682-1687
    PubMedGoogle Scholar
  • 11 Wilson PW, D’Agostino RB, Levy D. et al . Prediction of coronary heart disease using risk factor categories.  Circulation. 1998;  97 1837-1847
    CrossrefPubMedGoogle Scholar
  • 12 Giustina A, Barkan A, Casanueva FF. et al . Criteria for cure of acromegaly: a consensus statement.  J Clin Endocrinol Metab. 2000;  85 526-529
    CrossrefPubMedGoogle Scholar
  • 13 Giustina A, Melmed S. Acromegaly consensus: the next steps.  J Clin Endocrinol Metab. 2003;  88 1913-1914
    CrossrefPubMedGoogle Scholar
  • 14 Rakowski H, Appleton C, Chan KL. et al . Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography.  J Am Soc Echocardiogr. 1996;  9 736-760
    PubMedGoogle Scholar
  • 15 Schmermund A, Mohlenkamp S, Baumgart D. et al . Usefulness of topography of coronary calcium by electron-beam computed tomography in predicting the natural history of coronary atherosclerosis.  Am J Cardiol. 2000;  86 127-132
    CrossrefPubMedGoogle Scholar
  • 16 Agatston AS, Janowitz WR, Hildner FJ. et al . Quantification of coronary artery calcium using ultrafast computed tomography.  J Am Coll Cardiol. 1990;  15 827-832
    CrossrefPubMedGoogle Scholar
  • 17 Schmermund A, Mohlenkamp S, Berenbein S. et al . Population-based assessment of subclinical coronary atherosclerosis using electron-beam computed tomography.  Atherosclerosis. 2006;  185 177-182
    CrossrefPubMedGoogle Scholar
  • 18 Austen WG, Edwards JE, Frye RL. et al . A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association.  Circulation. 1975;  51 5-40
    CrossrefPubMedGoogle Scholar
  • 19 Colao A, Cuocolo A, Marzullo P. et al . Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study.  J Clin Endocrinol Metab. 1999;  84 1518-1523
    CrossrefPubMedGoogle Scholar
  • 20 Herrmann BL, Wessendorf TE, Ajaj W. et al . Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly.  Eur J Endocrinol. 2004;  151 309-315
    CrossrefPubMedGoogle Scholar
  • 21 Herrmann BL, Baumann H, Janssen OE. et al . Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up.  Exp Clin Endocrinol Diabetes. 2004;  112 225-230
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Colao A, Marzullo P, Cuocolo A. et al . Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.  Clin Endocrinol (Oxf). 2003;  58 169-176
    CrossrefPubMedGoogle Scholar
  • 23 Bruch C, Herrmann B, Schmermund A. et al . Impact of disease activity on left ventricular performance in patients with acromegaly.  Am Heart J. 2002;  144 538-543
    CrossrefPubMedGoogle Scholar
  • 24 Herrmann BL, Bruch C, Saller B. et al . Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy.  Clin Endocrinol (Oxf). 2002;  56 595-602
    CrossrefPubMedGoogle Scholar
  • 25 Bogazzi F, Lombardi M, Strata E. et al . High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging.  Clin Endocrinol (Oxf). 2008;  68 361-368
    PubMedGoogle Scholar
  • 26 Kahaly G, Olshausen KV, Mohr-Kahaly S. et al . Arrhythmia profile in acromegaly.  Eur Heart J. 1992;  13 51-56
    PubMedGoogle Scholar
  • 27 Cannavo S, Almoto B, Cavalli G. et al . Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography.  J Clin Endocrinol Metab. 2006;  91 3766-3772
    CrossrefPubMedGoogle Scholar
  • 28 Bogazzi F, Battolla L, Spinelli C. et al . Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study.  J Clin Endocrinol Metab. 2007;  92 4271-4277
    CrossrefPubMedGoogle Scholar
  • 29 Colao A, Spiezia S, Cerbone G. et al . Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly.  Clin Endocrinol (Oxf). 2001;  54 515-524
    CrossrefPubMedGoogle Scholar
  • 30 Erbel R, Schmermund A. Clinical significance of coronary calcification.  Arterioscler Thromb Vasc Biol. 2004;  24 e172 , author reply e172
    CrossrefPubMedGoogle Scholar
  • 31 Schmermund A, Baumgart D, Gorge G. et al . Coronary artery calcium in acute coronary syndromes: a comparative study of electron-beam computed tomography, coronary angiography, and intracoronary ultrasound in survivors of acute myocardial infarction and unstable angina.  Circulation. 1997;  96 1461-1469
    PubMedGoogle Scholar
  • 32 Herrmann BL, Brandt-Mainz K, Saller B. et al . Myocardial perfusion abnormalities in patients with active acromegaly.  Horm Metab Res. 2003;  35 183-188
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Fazio S, Cittadini A, Cuocolo A. et al . Impaired cardiac performance is a distinct feature of uncomplicated acromegaly.  J Clin Endocrinol Metab. 1994;  79 441-446
    CrossrefPubMedGoogle Scholar

Correspondence

B. L. HerrmannMD 

Division of Endocrinology and Diabetology

Technology Center

Universitätsstr. 142

44799 Bochum

Germany

Phone: +49/234/709 90 57

Fax: +49/234/709 90 58

Email: herrmann@endokrinologie-tzr.de

      >